316 related articles for article (PubMed ID: 21226542)
1. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
Kueppers F
Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
[TBL] [Abstract][Full Text] [Related]
2. [Lack of effect of substitution therapy of alpha1-antitrypsin deficiency].
Dahl R; Hilberg O; Løkke A; Pedersen L; Ringbæk T; Titlestad I
Ugeskr Laeger; 2011 Oct; 173(42):2645-7. PubMed ID: 22027165
[TBL] [Abstract][Full Text] [Related]
3. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
5. Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments.
Janciauskiene S; Welte T
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S280-8. PubMed ID: 27564662
[TBL] [Abstract][Full Text] [Related]
6. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.
Hubbard RC; Crystal RG
Am J Med; 1988 Jun; 84(6A):52-62. PubMed ID: 3289387
[TBL] [Abstract][Full Text] [Related]
7. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
8. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
[TBL] [Abstract][Full Text] [Related]
9. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.
Parr DG; Lara B
Drug Des Devel Ther; 2017; 11():2149-2162. PubMed ID: 28769553
[TBL] [Abstract][Full Text] [Related]
11. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches.
Santangelo S; Scarlata S; Poeta ML; Bialas AJ; Paone G; Incalzi RA
Curr Med Chem; 2017; 24(1):65-90. PubMed ID: 27855621
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
14. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
16. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.
Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2010 Jul; (7):CD007851. PubMed ID: 20614465
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for alpha-1-antitrypsin deficiency.
Stockley RA
Expert Opin Emerg Drugs; 2010 Dec; 15(4):685-94. PubMed ID: 20716026
[TBL] [Abstract][Full Text] [Related]
18. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
20. Lung disease due to alpha 1-antitrypsin deficiency.
Wiedemann HP; Stoller JK
Curr Opin Pulm Med; 1996 Mar; 2(2):155-60. PubMed ID: 9363132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
